EP2935251A1 — Deuterated alk inhibitors
Assigned to Concert Pharmaceuticals Inc · Expires 2015-10-28 · 11y expired
What this patent protects
This invention relates to novel ALK inhibitors of Formula I: as defined in the specification, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating d…
USPTO Abstract
This invention relates to novel ALK inhibitors of Formula I: as defined in the specification, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering ALK inhibitors.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.